Radiomics in prostate cancer: An up-to-date review
M Ferro, O de Cobelli, G Musi… - Therapeutic …, 2022 - journals.sagepub.com
Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male
population. The diagnosis, the identification of aggressive disease, and the post-treatment …
population. The diagnosis, the identification of aggressive disease, and the post-treatment …
Magnetic resonance imaging based radiomic models of prostate cancer: A narrative review
Simple Summary The increasing interest in implementing artificial intelligence in radiomic
models has occurred alongside advancement in the tools used for computer-aided …
models has occurred alongside advancement in the tools used for computer-aided …
Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2. 1 categories on prostate MRI
R Girometti, G Giannarini, V Panebianco… - The British journal of …, 2022 - academic.oup.com
Objectives: To compare the effect of different PSA density (PSAD) thresholds on the
accuracy for clinically significant prostate cancer (csPCa) of the Prostate Imaging Reporting …
accuracy for clinically significant prostate cancer (csPCa) of the Prostate Imaging Reporting …
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA‐related parameters to enhance the detection of clinically significant …
Z Zhou, Z Liang, Y Zuo, Y Zhou, W Yan, X Wu… - The …, 2022 - Wiley Online Library
Abstract Objective Prostate cancer (PCa) is the most prevalent cancer among males. This
study attempted to develop a clinically significant prostate cancer (csPCa) risk nomogram …
study attempted to develop a clinically significant prostate cancer (csPCa) risk nomogram …
Diagnostic value of combining PI-RADS v2. 1 with PSAD in clinically significant prostate cancer
X Wei, J Xu, S Zhong, J Zou, Z Cheng, Z Ding… - Abdominal …, 2022 - Springer
Purpose To investigate the diagnostic value of the Prostate Imaging Reporting and Data
System version 2.1 (PI-RADS v2. 1) for clinically significant prostate cancer (CsPCa). We …
System version 2.1 (PI-RADS v2. 1) for clinically significant prostate cancer (CsPCa). We …
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement
DA Ferraro, AM Hötker, AS Becker, I Mebert… - European Journal of …, 2022 - Springer
Background Magnetic resonance imaging (MRI) is recommended by the European Urology
Association guidelines as the standard modality for imaging-guided biopsy. Recently …
Association guidelines as the standard modality for imaging-guided biopsy. Recently …
An apparent diffusion coefficient-based machine learning model can improve prostate cancer detection in the grey area of the prostate imaging reporting and data …
C Gaudiano, M Mottola, L Bianchi, B Corcioni… - Cancers, 2023 - mdpi.com
Simple Summary Multiparametric Magnetic Resonance Imaging (mpMRI) interpretation and
reporting is based on the more recent version 2.1 of the Prostate Imaging-Reporting and …
reporting is based on the more recent version 2.1 of the Prostate Imaging-Reporting and …
Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions
R Girometti, G Giannarini, M De Martino… - European Journal of …, 2023 - Elsevier
Purpose To identify clinical and multiparametric magnetic resonance imaging (mpMRI)
factors predicting false positive target biopsy (FP-TB) of prostate imaging reporting and data …
factors predicting false positive target biopsy (FP-TB) of prostate imaging reporting and data …
Artificial intelligence as diagnostic aiding tool in cases of Prostate imaging reporting and data system category 3: the results of retrospective multi-center cohort study
K Wang, Z Xing, Z Kong, Y Yu, Y Chen, X Zhao… - Abdominal …, 2023 - Springer
Purpose To study the effect of artificial intelligence (AI) on the diagnostic performance of
radiologists in interpreting prostate mpMRI images of the PI-RADS 3 category. Methods In …
radiologists in interpreting prostate mpMRI images of the PI-RADS 3 category. Methods In …
Natural History of Patients with Prostate MRI Likert 1-3 and Development of RosCaP: A Multivariate Risk Score for Clinically Significant Cancer
L Orecchia, A Nardi, P Fletcher, S Ippoliti… - Clinical Genitourinary …, 2023 - Elsevier
Introduction Clinically significant prostate cancer (csCaP) with Gleason≥ 3+ 4 is found in
10% negative prebiopsy multiparametric (mp) MRI cases and varies widely for equivocal …
10% negative prebiopsy multiparametric (mp) MRI cases and varies widely for equivocal …